EUVIMEDEUVIMED entdecken
Crossref

Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing

Daniele Armenia, Claudia Alteri, Valeria Micheli iD, Tiziano Allice, Celestino Bonura, Bianca Bruzzone iD, Isabella Bon, Romina Corsini, Alessandro Zerbini, Loriana Morelli, Francesco Cerutti iD, Giovanni Giammanco und 9 weitere

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Daniele Armenia und 20 weiteren Autor:innen. Beteiligte Einrichtung: Departmental Faculty, UniCamillus, Saint Camillus International University of Health Sciences, Via di Sant'Alessandro, 8, Rome 00131, Italy. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Gilead Sciences, Janssen Infectious Diseases & Vaccines, ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monitoring HIV-1 subtype circulation and transmitted drug resistance (TDR) remains a key priority, particularly since the rollout of high-sensitivity next-generation sequencing (NGS).

Methods

Routine plasma HIV-1 RNA NGS genotyping data were collected from newly diagnosed individuals in Italy over 2022–24. HIV-1 TDR and genotypic susceptibility were evaluated through HIVdb with NGS set at 10% and 20%. Subtype and transmission clusters (TC) were determined through the maximum likelihood phylogeny based on the GTR + F + R9 model.

Results

Seven hundred and forty-two individuals were included, 51.9% harbouring non-B strains [CRF02_AG (18.1%); CRF BF (6.1%); A1/A3/A6 (7.1%); others (20.5%)]. TDR prevalence to any class was 11.7% at Sanger-like NGS-setting (>20%), slightly increased (15.0%) at 10% NGS-setting, and significantly varied across subtypes, with the highest prevalence observed in B subtype. Most antiretrovirals showed full genotypic activity in nearly 99% of individuals, except for efavirenz and rilpivirine (proportion of individuals with full activity <92%). A total of 57 TC were detected: 40 pairs, 17 clusters (>2 sequences). Thirteen TC (22.8%, 8 pairs, 5 clusters) involved individuals harbouring TDR. TDR was detected as minority mutations in five TC.

Conclusions

A high proportion of HIV-1 non-B subtypes circulate in Italy. TDR prevalence is around 12% using NGS at Sanger-like threshold and moderately increases to 15% when NGS is set at 10%. However, the impact of the detected TDR on the susceptibility to currently used antiretrovirals in clinical practice is negligible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsDrug Resistance, ViralAnti-HIV AgentsHumansItalyHigh-Throughput Nucleotide SequencingGenotypeFemalePhylogenyMaleRNA, ViralAdultPrevalenceMiddle Aged

Substanzen

Anti-HIV AgentsRNA, Viral

Autor:innen und Institutionen

  • Departmental Faculty, UniCamillus, Saint Camillus International University of Health Sciences, Via di Sant'Alessandro, 8, Rome 00131, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Microbiology and Virology Unit, IRCCS Fondazione Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Clinical Microbiology, Virology and Bioemergency Diagnostics, ASST Fatebenefratelli Sacco-University of Milan, Milan, Italy.
  • Laboratory of Microbiology and Virology, ASL CdT, Amedeo di Savoia Hospital, Turin, Italy.
  • Department of Health Promotion, Mother and Child Care, Internal Medicine, and Medical Specialties "G D'Alessandro", Universita' degli Studi di Palermo, Palermo, Italy.

ORCID-Profile: Valeria Micheli, Bianca Bruzzone, Francesco Cerutti

Förderung

  • Gilead Sciences
  • Janssen Infectious Diseases & Vaccines
  • ViiV Healthcare

Zitieren

APA

Armenia, D., Alteri, C., Micheli, V., Allice, T., Bonura, C., Bruzzone, B., Bon, I., Corsini, R., Zerbini, A., Morelli, L., Cerutti, F., Giammanco, G., Randazzo, N., Bertoldi, A., Novazzi, F., Ibba, G., Bertoli, A., Bezenchek, A., Ceccherini-Silberstein, F., …, & Santoro, M. M. (2026). Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag084

Vancouver

Armenia D, Alteri C, Micheli V, Allice T, Bonura C, Bruzzone B, et al. Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag084

BibTeX
@article{Armenia2026,
  author = {Armenia, Daniele and Alteri, Claudia and Micheli, Valeria and Allice, Tiziano and Bonura, Celestino and Bruzzone, Bianca and Bon, Isabella and Corsini, Romina and Zerbini, Alessandro and Morelli, Loriana and Cerutti, Francesco and Giammanco, Giovanni and Randazzo, Nadia and Bertoldi, Alessia and Novazzi, Federica and Ibba, Gabriele and Bertoli, Ada and Bezenchek, Antonia and Ceccherini-Silberstein, Francesca and Zazzi, Maurizio and Santoro, Maria Mercedes},
  title = {Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag084}
}
Kostenlos starten →